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ABSTRACT 
 
Australia’s health system is characterised by an ongoing tension between a commitment to 
utility and a commitment to individual rights. This tension is particularly problematic for the 
Australian Government when deciding which cancer medicines to add to the Pharmaceutical 
Benefits Scheme to make cheaper for patients. This paper investigates how the right to the 
highest attainable standard of health has influenced decisions about funding high cost 
cancer medicines in Australia. We then consider the value of the right to health for funders 
and conclude that resource allocation decisions should not be entirely informed by the right 
to health. We maintain that instead, regard should be had to the cost-effectiveness and 
affordability of cancer treatments before they are subsidised.  
 
INTRODUCTION 
 
In Australia, two decision-making bodies control access to medicines. The first is the 
Therapeutic Goods Administration, which determine whether medicines are sufficiently safe 
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and efficacious to be given marketing approval.2 Next is the Pharmaceutical Benefits 
Advisory Committee (PBAC), which assesses the economics of introducing new medicines 
into the health system.3 If both bodies are satisfied, the government will then negotiate 
prices for new medicines with drug sponsors and then list the drugs on the Pharmaceutical 
Benefits Scheme (PBS).  
 
If medicines are not included on the PBS, patients in the community have to seek access 
through other avenues. Other avenues include access through hospitals, pharmaceutical 
industry compassionate access schemes and self-funding. All of these mechanisms have 
their problems, particularly when medicines are very expensive, as is the case for many new-
targeted therapies that have entered the market. For instance, prior to the listing of 
Keytruda for metastatic melanoma on the PBS, it cost patients $156,130 per year of 
treatment.4  
 
While there is a strong ethical imperative to add drugs outside the financial reach of the 
average Australian onto the PBS, doing so is a major contributor to increases in PBS 
spending. The National Commission of Audit has stated that PBS spending has increased in 
recent years, particularly because of a growing demand for pharmaceuticals, an aging 
population, and the increasing incidence of chronic disease.5 The Commission of Audit 
predicts that PBS spending will increase from approximately $9 billion to more than $15 
billion by 20236 - this is in addition to the 13 per cent yearly growth of the PBS since 2005.7 
 
These challenges have led to numerous debates about access to high cost medicines in 
Australia. For example, on 3 December 2014, the Australian Senate commissioned the 
Senate Community Affairs References Committee to report on the ‘availability of new, 
innovative and specialist cancer drugs in Australia.’8 In particular, the Committee was 
charged with focusing on issues related to: (a) timing of access and affordability for patients; 
(b) how the PBAC and PBS handles these medicines, and the impact of delays in approval on 
patients; and (c) the impact of the quality of care to cancer patients.9  
 
The Committee received over 200 submissions from individual consumers, pharmaceutical 
companies, research collaboratives, patient advocacy groups, physicians and special interest 
groups. A public hearing was also held in Canberra. In order to address inefficiencies 
associated with the processes that evaluate new cancer medicines, the Senate report arising 
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from the inquiry recommended a comprehensive review of current systems for registration 
and subsidisation of medicines.10 
 
It is clear from the Senate report that there is a strong belief that patients ought to be able 
to access medicines that relieve their suffering and prolong their lives, and it is the 
government’s responsibility to find solutions to ensure that medicines remain accessible to 
all. This view is akin to the basic tenet of the right to the highest attainable standard of 
health – an internationally recognised human right owed to all peoples. This right to health 
obliges states to provide basic medical services for their entire population, including those 
who suffer from chronic diseases.  
 
The general public seems to be alert to the existence of such a right. For example, some 
patients submitted to the Senate inquiry that being denied access to medicines because of 
affordability was unfair. One individual stated about another; 
 
“On top of the extreme suffering he has endured fighting this wretched 
disease, the added torment of knowing there is a drug which could help him, 
but at a huge cost is very unfair.”11 
 
Nonetheless, despite the right to health potentially being relevant to discussions about high 
cost drug funding, it was not explicitly consider at any point in the Community Affairs 
References Committee report. From this finding, one might hypothesise that the right to 
health is not explicitly present in Australian health policy, but rather, is only used for 
rhetorical purposes. 
 
The aim of this paper is to investigate whether this is in fact accurate – that is, whether the 
right to health plays any explicit, or implicit, role in Australian health policy. More 
specifically, we will assess the role that the right to health might play in decisions about the 
funding of high cost medicines.  
 
We begin by describing international and national laws that mention to right to health or a 
right to access medicines. We then present the results of a systematic search we conducted 
of Australian laws and health policies, looking for either explicit references to the right to 
health, or policy assumptions that imply that such a right to health might exist. 
 
The results of this investigation are then used to make an informed assessment about 
whether, and to what extent, the right to health influences the Australian health system. 
Further, we consider the potential value of the right to health for those policymakers tasked 
with the duty of ensuring fair and equitable access to high cost medicines in Australia.   
 
MATERIALS AND METHODS 
 
The international laws relevant to this subject were located using the World Health 
Organisation website and the Officer of the High Commissioner for Human Rights website. In 
the search bar of both websites, appropriate terms were searched for that included: “right 
to health,” “right to health care,” “right to the highest attainable standard of health,” 
“access to health*,” “right to medicine*,” “right to pharmaceutical*,” “right to drug*,” 
“access to medicine*,” “access to pharmaceutical*”, “access to drug*,” “right to essential 
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medicine*,” and “access to essential medicine*.” 
 
Relevant domestic laws were located using the Commonwealth Department of Health 
website, and the ComLaw website. Each law was searched for any mention of the word or 
words: “right,” “access,” “equit*,” “fair*,” “just*,” “right to health*” and “essential 
medicine*.” Further, the second reading speech for each of the relevant domestic laws was 
located using the Parliament of Australia website. Each second reading speech was searched 
for any mention of the word/s: “right,” “access,” “equit*,” “fair*,” “just*,” “right to health*” 
and “essential medicine*.”  
 
Domestic policies relevant to this paper were located using the Department of Health 
website and the Parliament of Australia website. The same searching process above was 
employed. 
 
To locate relevant academic literature on the right to health, Google Scholar, Global Health, 
Informit Online, Embase.com, and AGIS Plus Text were searched. Key words that were used 
when searching in these databases included “human rights health”, “right to health”, “right 
to cancer”, “access* cancer”, “health* access*” and “health* equity”. No date or other limits 
were placed on the search. All articles and websites were accessed between August and 
November 2015. 
 
RESULTS 
 
We identified 13 relevant international laws, 16 relevant domestic laws, and 3 relevant 
domestic policies.  
 
International ‘right to health’ laws  
 
According to international law, every person has a right to the highest attainable standard of 
health.12 Like all human rights, the right to health is owed to all human beings, irrespective 
of their race, gender, place of residence, or other status.13 
 
The first formal international document to recognise the right to health was the Constitution 
of the World Health Organisation 1946.14 It alludes to the right to health in both its 
preamble, and in Article 1. Article 1 of the Constitution of the World Health Organisation 
1946 states that: 
 
“The objective of the World Health Organisation shall be the attainment by all 
peoples of the highest possible level of health.” 15 
 
The Universal Declaration of Human Rights 1948,16 which was drafted just two years later, 
also recognises the right to health in Article 25(1). It states that:  
 
“Everyone has the right to a standard of living adequate for the health and well-
being of himself and of his family, including food, clothing, housing and medical care 
and necessary social services...”17 
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Both the Constitution of the World Health Organisation 1946 and the Universal Declaration 
of Human Rights 1948 drew attention to health at the global level. Nonetheless, neither law 
enforces countries to provide adequate health care within their borders. This is because 
neither is binding on states – a state is able to choose whether they wish to meet the 
standards set out in both laws, and very few states have done so. Thus, to actualise positive 
health outcomes for people in nation states, enforceable human rights laws were required. 
 
The first international document to make the right to health enforceable in international law 
was the International Covenant on Economic and Social Rights 1976 (ICESCR).18 The ICESCR is 
a multilateral treaty that requires states to take steps, including legislative measures, to 
realise the rights listed within it.19  The right to health is one of the listed rights - it is 
protected in Article 12, which states that: 
 
‘The State Parties to the present Covenant recognise the right of everyone to the 
enjoyment of the highest attainable standard of physical and mental health.’20  
 
Article 12 of the ICESCR also sets out four steps to be taken by the State parties to the 
ICESCR to achieve the full realisation of the right to health. These are: 
 
“(a) The provision for the reduction of the stillbirth-rate and of infant mortality and 
for the healthy development of the child; 
(b) The improvement of all aspects of environmental and industrial hygiene;  
(c) The prevention, treatment and control of epidemic, endemic, occupational and 
other diseases; 
(d) The creation of conditions which would assure to all medical service and medical 
attention in the event of sickness.”21 
 
Article 12 of the ICESCR is the most comprehensive statement on the right to health in 
international law.22 It has transformed health from a national concern, into a global priority. 
Nonetheless, Article 12 of the ICESCR does not give any indication of how far the right to 
health is intended to extend, nor does it specify how, or to what extent, states are expected 
to achieve the four steps outlined.23  
 
To address this issue the United Nations’ Committee on Economic, Social and Cultural Rights 
issued General Comment No. 14: The right to the highest attainable standard of health 2000 
(General Comment No. 14). General Comment No. 14 provides more explicit direction on 
the right to health than does Article 12 of the ICESCR, and has therefore assisted policy-
makers translate the right to health into domestic laws. 
 
Notable provisions in General Comment No.14 include: 
 
“4. …the highest attainable standard of physical and mental health is not confined to 
the right to health care.  
 
7. The right to health is not to be understood as a right to be healthy…[the right to 
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health] include[s] the right to a system of health protection[,], which provides 
equality of opportunity for people to enjoy the highest attainable level of health. 
 
12. The right to health in all its forms and at all levels contains the following 
interrelated and essential elements… (a) Availability… (b) Accessibility… (c) 
Acceptability… (d) Quality …”24 
 
Importantly, General Comment No. 14 clarifies that the right to health is a ‘progressively 
realisable’ right. This means that States must meet the provisions in Article 12 of the ICESCR 
as closely as possible, but are not expected to provide health care measures that they 
cannot afford.25 However, General Comment No. 14 does emphasise that the ‘progressively 
realisable’ nature of the right to health should not be “interpreted as depriving States 
parties’ obligations of all meaningful content.” 26 All states are still required to employ 
appropriate means at all levels of government to realise the right to the extent that they can 
afford. However, because General Comment No. 14 does not specify how much a state 
should expend on health, in practice it has been difficult for states to define and meet their 
obligations.  
 
Despite this shortcoming, all states are required to effect a number of provisions, called 
‘core obligations.’ These obligations are non-negotiable. General Comment No. 14 states 
that these core obligations include: “ 
 
(a) To ensure the right of access to health facilities, goods and services on a non-
discriminatory basis, especially for vulnerable or marginalized groups; 
(b) To ensure access to the minimum essential food which is nutritionally adequate 
and safe, to ensure freedom from hunger to everyone; 
(c) To ensure access to basic shelter, housing and sanitation, and an adequate 
supply of safe and potable water; 
(d) To provide essential drugs, as from time to time defined under the WHO Action 
Programme on Essential Drugs;” 27 
 
The right to health has also been recognised in subsequent international human rights 
legislation including: Article 5 (e)(iv) of the International Convention on the Elimination of All 
Forms of Racial Discrimination 1965, Articles 11(1) and 12 of the Convention on the 
Elimination of All Forms of Discrimination against Women 1979 and Article 24 of the 
Convention on the Rights of the Child 1989. 
 
Several regional human rights instruments also recognise the right to health, such as: Article 
11 of the European Social Charter 1961, Article 16 of the African Charter on Human and 
Peoples' Rights 1981, and Article 10 of the Additional Protocol to the American Convention 
on Human Rights in the Area of Economic, Social and Cultural Rights 1988. 
 
Every state in the world is a signatory to at least one international human rights treaty that 
addresses health-related rights.28 This suggests that the basic premise of the right to health 
is widely, if not universally, supported. 
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International ‘right to medicines’ laws 
 
According to General Comment No. 14, states must take positive steps to ensure that 
essential medicines are accessible to all.29 The World Health Organisation defines essential 
medicines as “those [medicines] that satisfy the priority health care needs of the 
population.”30  
 
Essential medicines are selected with regard to public health relevance, evidence of efficacy 
and safety, and comparative cost-effectiveness.31 The World Health Organisation’s Essential 
Medicines List is a catalog of medicines that the World Health Organisation believe satisfy 
the aforementioned criterion, and thus need to be accessible to all people. 
 
More specifically, General Comment No. 14 stipulates that states must ensure:  
 
“(a) The availability of essential medications in sufficient quantity;  
(b) The accessibility of the medication to everybody (including physical and 
economic accessibility);  
(c) The acceptability of the treatment with respect to the culture and ethics of the 
individual; and 
(d) An appropriate quality of the medication.”32  
 
While these objectives are admirable, they are unfeasible for a number of developing 
countries. The World Health Organisation recognises this, and instead encourages these 
states to prepare their own national essential medicines lists.33 States are then required to 
make available and accessible the essential medicines on their national list. Four out of five 
countries globally now have national essential medicines lists.34 
 
International ‘right to high-cost medicines’ laws  
 
If a high cost medicine is listed on the World Health Organisation Essential Medicine List or 
an applicable National Essential Medicine List, then, as with any other essential medicine, 
states must ensure that it the medicine is economically accessible to all people in the 
relevant jurisdiction. 
 
For the most part, high-cost medicines have been absent from the World Health 
Organisation Essential Medicines List and from the majority of national lists around the 
world. This is due to fact that, until recently, a medicine needed to be considered cost-
effective and affordable in order for it to be listed as essential. 
 
This changed in 2001, when the WHO’s Executive Board reviewed methods for the selection 
of essential medicines.35 The Executive Board noted that absolute treatment cost should not 
be a reason to reject a proposed addition to the model list if criteria for benefit and public 
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health relevance are met. In doing so, affordability changed from a precondition for listing 
an essential medicine to a consequence that must be managed after the decision to list.36 
 
The implementation of the concept of essential medicines still, however, remains flexible 
and adaptable to many different situations; exactly which medicines are regarded as 
essential remains a national responsibility.37 Nonetheless, this change has resulted in a 
number of high-cost medicines since being added to the WHO Essential Medicines List, 
including medicines for cancer, hepatitis C, multidrug-resistant tuberculosis and new oral 
anticoagulants.38 For example, 16 new cancer medicines were added to the WHO Essential 
Medicines List in 2015.39 The addition of these 16 cancer agents to the WHO Essential 
Medicines List has extended the chapter of cancer medicines from 30 to 46. Notably, three 
of the new drugs – imatinib (Gleevec, Novartis), rituximab (Rituxan, Genentech), and 
trastuzumab (Herceptin, Genentech) are expensive ‘targeted’ cancer therapies (for instance 
imatinib costs $4,500 per month of treatment in the United States).40 
 
It is arguable that, with removal of its cost-effectiveness criterion, the Essential Medicines 
List is now more aspirational than it is practical. This is because nation states have limited 
funds for health, and using these funds on expensive medicines may create massive 
disparities in health care spending, and create inequities in other areas of the health system. 
However, the addition of high cost medicines to the WHO Essential Medicines List may 
inspire developed countries, who can afford these high-cost medicines, to consider adding 
similar medicines to their own national lists, or consider taking further actions, such as 
issuing compulsory licenses, to make expensive medicines more affordable.41 
 
Australian human rights laws 
 
Australia is a party to seven of the major international human rights treaties42 including the 
ICESCR – the ‘right to health’ law. However, because international law is not automatically 
enforceable in Australia (domestic enabling legislation is needed), the international right to 
health is not justiciable in Australia. No domestic legislation that explicitly protects the right 
to health has been passed to date.  
 
Despite this, the Australian Government has consistently stated that it supports the right to 
health described in the ICESCR,43 and has admitted that Australia has the resources to adopt 
legislative, budgetary, judicial and administrative measures that effectively realise the right 
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to health. 44 What Australia does have is a health rights charter – a summary of the health 
related rights recognised in Australia. This summary is called The Australian Charter of 
Healthcare Rights 2008 (Charter).45 The Charter has three guiding principles, one of which is, 
‘everyone has a right to the highest possible standard of physical and mental health [in 
Australia].’46 Notably, this is the same right as that protected by the ICESCR. 
 
The Charter is, however, not based in legislation, and as such, has no legal influence. While 
some domestic health policies such as PD2011.022 Your Rights and Responsibilities 2011 
(NSW) do mandate that, ‘All health professionals delivering healthcare services within NSW 
Health must be made aware of the detailed rights and responsibilities outlined in [The 
Australian Charter of Healthcare Rights]’47 these rights have never been the subject of 
litigation in Australia. 
 
State and territory human rights laws 
 
At the State level, only the Australian Capital Territory and Victoria have human rights 
charters that protect and enforce a variety of human rights in their jurisdictions – the 
Human Rights Act 2004 (ACT) and the Charter of Human Rights and Responsibilities 2006 
(VIC). Both laws explicitly protect civil and political rights only.48 Thus, the right to health, a 
‘social’ right, is not particularised in either law.    
 
However, this does not mean that the right to health can be freely violated. In Section 7 of 
the Human Rights Act 2004 (ACT), it is stated that: 
 
“Rights apart from Act 
This Act is not exhaustive of the rights an individual may have under domestic or 
international law.  
Examples of other rights 
... rights under the ICESCR [International Covenant on Economic, Social and Cultural 
Rights (1966)] not listed in this Act.”49 
 
Similarly, in Section 5 of the Charter of Human Rights and Responsibilities Act 2006 (VIC) it is 
stated that: 
 
“A right or freedom not included in this Charter that arises or is recognised under 
any other law (including international law…) must not be taken to be abrogated or 
limited only because the right or freedom is not included in this Charter”50 
 
Both sections ensure that an individual’s right to health, as provided for in international law, 
cannot be discredited by virtue of the aforementioned sections.51 
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Further, the civil and political rights contained in both Acts can occasionally be used to 
indirectly protect the right to health. For example, in Castles v The Secretary to the 
Department of Justice [2010] VSC 310, a prisoner sought a declaration that they were 
entitled to continue the IVF treatment that they were receiving prior to being imprisoned. 
They argued that the decision not to allow her to access IVF was a breach of her rights to 
family life and privacy under the Charter of Human Rights and Responsibilities Act 2006 
(VIC). Emerton J found that the Corrections Act 1986 (VIC) s 47(1)(f) conferred on Castles the 
right to continue to undergo IVF treatment.  
 
Other Australian laws that allude to a ‘right to health’ 
 
Responsibility for health care in Australia is split between the Commonwealth and State 
Governments.52 At both the Commonwealth and State levels, there are a number of health-
related laws that implicitly suggest that there might be such a thing as a (limited) right to 
health in Australia. 
 
The Commonwealth government has the power to legislate on pharmaceutical, sickness and 
hospital benefits, as well as medical and dental services.53A number of Commonwealth laws 
deal with subjects relevant to the right to health, including the Health Insurance Act 1973 
(Cth) and the National Health Act 1953 (Cth). 
 
Health Insurance Act 1973 (Cth) 
 
The Health Insurance Act 1973 (Cth) introduced Medicare (Medibank at the time) in 197554 – 
a Commonwealth funded healthcare scheme that enables all residents of Australia to be 
automatically covered by medical and hospital benefits.55  
 
Prior to 1975, most Australians had private health insurance, but some remained uninsured. 
The government sought to remove this disparity by introducing a universal health insurance 
that could be accessed by all Australians.56 In the Second Reading Speech for the Health 
Insurance Bill `1973 (Cth), Mr Hayden MP stated that Medibank sought to establish ‘social 
equity in health insurance’57 and that his government believed that this task was ‘an 
obligation.’58 Further, he stated:  
 
“Our program gives true freedom. It gives freedom from fear of the financial 
consequences of illness, it gives freedom of choice of doctor and hospital and it does 
this in a way which does not levy a penalty on the sick and the economically less 
fortunate members of the community…Our program is not one which stems from 
doctrinaire beliefs but it is one which flows from a sense of social justice. It is a 
program which rejects the belief that health care is a commodity to be traded rather 
than a social utility to be used to improve the quality of living…It is indeed a program 
which must cause this Parliament to decide whether health care is to be a privilege 
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to be purchased or a right to be enjoyed equally by every Australian.” 59 
 
Here, Mr Hayden MP lucidly characterises health as a ‘right’; a ‘right’ that is owed to all 
Australians without economic or health-related discrimination. Thus, it appears that 
Medicare is, at its core, a fundamentally human rights based program.   
 
The use of rights language to describe Medicare has continued in more recent year. For 
example, Mr Blewett MP (Health Minister 1983-1987) described the underpinning attributes 
of Medicare as: 
 Simplicity: “the simpler we made a health scheme the more chance it has of 
delivering the services to those who need them most” 
 Affordability: “everyone will contribute towards the nation’s health costs according 
to his or her ability to pay” 
 Universality: “Medicare will provide the same entitlement to basic medical benefits, 
and treatments in a public hospital to every Australian resident regardless of 
income” 
 Efficiency: “Having the maximum number of health dollars spent on delivering 
health services rather than administering them” 60 
These attributes are remarkably similar to the core principles of the right to health as 
outlined in Article 12 of the ICESCR. For example ‘universality’ is similar to Part (d) of Article 
12 of the ICESCR: ‘the creation of conditions which would assure to all medical service and 
medical attention in the event of sickness.’61  
 
Further, rights language is used throughout the Health Insurance Act 1973 (Cth). For 
example, the Act refers to a ‘right to use [medical] equipment’62 and a ‘right to payment of 
benefits.’63 Further, the Health Insurance Act 1973 (Cth) lists the ‘Rights of persons under 
review at hearings [relating to health].’64 
 
It is noteworthy, however, that while Section 26 of the Health Insurance Act 1973 (Cth) used 
to recognise the rights of patients to treatment, this provision has since been removed. So 
too have the Medicare Commitments that the Commonwealth, States and Territories were 
once expected to follow.65  
 
National Health Act 1953 (Cth) 
 
The National Health Act 1953 (Cth) makes provision for pharmaceutical, sickness and 
hospital benefits. Today, the National Health Act 1953 (Cth) underpins the Pharmaceutical 
Benefits Scheme – a program that provides subsidised prescription drugs to Australian 
residents.66 It also contains extensive provisions about the operation of nursing homes.  
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Although the National Health Act 1953 (Cth) does not explicitly use rights language, it does 
require that essential medicines be economically accessible in Australia, which is a key 
objective of the international right to health. In Australia, essential medicines are defined as 
medicines that are necessary to maintain the health of the community in a way that is cost-
effective to the public.67 
 
Other relevant laws include the Aged Care Act 1997 (Cth), the Disability Services Act 1986 
(Cth), the Veterans’ Entitlements Act 1986 (Cth), the Military Rehabilitation and 
Compensation Act 2004 (Cth) and the Australian Institute of Health and Welfare Act 1987 
(Cth) - all of which focus on various health-related entitlements. 
 
Domestic ‘right to medicines’ policies 
 
National Medicines Policy 
 
The National Medicines Policy, introduced in 1999, is a framework designed to ensure that 
all Australians have access to quality medicines.68 It is the primary authority on how 
medications are to be handled in Australia, both through the PBS and alternate access 
schemes. The National Medicines Policy has four central objectives:  
 
 Timely access to the medicines that Australians need, at a cost individuals and the 
community can afford; 
 Medicines meeting appropriate standards of quality, safety and efficacy; 
 Quality use of medicines; and 
 Maintaining a responsible and viable medicines industry69 
 
Whilst these objectives had already been implied in Medicare and PBS purpose statements 
prior to 1999 (for example, Medicare and the PBS both protect ‘access’ for all Australians), 
the National Medicines Policy satisfies the World Health Organisation’s desire for Australia 
to have a clear therapeutic drug strategy.70 Further, since its inception in 1999, lawmakers 
have had to ensure that new health laws support the four objectives of the National 
Medicines Policy.  
 
In 2014, Tim Watts MP criticised the National Health Amendment (Pharmaceutical Benefits) 
Bill 2014 (Cth), which proposed to increase the PBS safety net, because, “The National 
Medicines Policy aims to achieve positive health outcomes for all Australian through access 
to and wise use of medicines. It is difficult to see how the bill before the House conforms to 
these objectives [“timely access to the medicines that Australians need, at a cost individuals 
and the community can afford”].71 This suggests that the National Medicines Policy does 
inform domestic health laws, and ensures that potential health laws do not disadvantage the 
(sick) individual.  
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Pharmaceutical Benefits Scheme 
 
The principal mechanism for ensuring access to medicines in Australia is the Pharmaceutical 
Benefits Scheme (PBS). The PBS provides Australians with affordable access to necessary 
medicines.72 It does this by subsiding the cost of approximately 80% of the medications 
dispensed in Australia.73 
 
The first attempt to legislate for the provision of free pharmaceuticals came in 1944 in the 
Pharmaceutical Benefits Act 1944 (Cth). In the Second Reading Speech for the 
Pharmaceutical Benefits Act 1944 (Cth), the government stated: 
 
“Any man, who is honest and thrifty can, so long as he remains well, provide to 
some degree against the economic accidents of life, but he cannot foresee an illness 
which may disable him…the Government, therefore, intends to relieve the citizen, as 
far as possible, from the economic burdens of illness…this must, necessarily, involve 
the provision of medicine.”74 
 
This statement suggests that the PBS sought to eliminate economic discrimination against 
the sick, and to ensure that all Australians can access medicinal remedies for their illnesses. 
However, the High Court of Australia, with only one dissentient, shortly after declared the 
Act unconstitutional because the Commonwealth did not have the power to spend money 
on the provision of medicines.75 In response, the Government held a national referendum76 
in 1946 to extend the powers of government over a range of social services, including 
pharmaceutical benefits.77 Dr Evatt, who introduced the referendum bill to Parliament, 
stated, “Not only in Australia, but also throughout the world, it is the community’s duty to 
provide for its members benefits of a social service character.”78 The referendum was 
successful - a majority (54.39%) of the Australian public agreed that the government had a 
‘duty’ to provide social service benefits to them. The referendum amendment introduced 
Section 51 (xxiiiA) into the Constitution of Australia 1901 (Cth), which reads: 
 
 “The provision of maternity allowances, widows’ pensions, child  
endowment, unemployment, pharmaceutical, sickness and hospital benefits, 
medical and dental services (but not so as to authorize any form of civil 
conscription), benefits to students and family allowances.”79 
 
After the amendment, the Pharmaceutical Benefits Bill 1947 (Cth) was reintroduced to the 
Commonwealth Parliament. In the Second Reading Speech, Senator McKenna stated that 
the “scheme is designed to lessen the economic barrier between the patient and efficient 
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treatment for his illness or incapacity.”80 Equal access to medicines, without regard to 
wealth, appeared to be the key philosophy of the early Pharmaceutical Benefits Scheme. 
Notable however is that relatively few prescriptions were covered under it because of 
opposition from the medical profession.81 
 
With the election of the Liberal government in 1949, the comprehensive scheme proposed 
under the 1947 Labor legislation was altered.82 Concerned about the expense of the scheme, 
the new government introduced a limited scheme in 1950 to provide a list of 139 ‘life saving 
and disease preventing drugs’ free of charge to the whole community.83  
The Pharmaceutical Benefits Scheme as we know it today, was introduced in 1960 following 
the passage of the National Health Act No. 72 1959 (Cth). In the new scheme, there was an 
expanded range of subsidised drugs for the general public and the introduction of a patient 
contribution of 5 shillings to provide some control on volumes and expenditure.84 In the 
Bill’s Second Reading Speech, Pr Cameron MP stated that the reason for a co-payment was 
because, “the cost of pharmaceutical benefits could soon exceed £30,000,000 a year, and 
would dominate the entire national health service, leaving correspondingly less room for 
manoeuvre for improvements and operations in any other direction…it is not in the interests 
of the public that a scheme of social benefit should be unstable and uncontrolled in the 
amount it costs…”85  
However, many politicians at the time were opposed to this change, arguing, as Mr Clarey 
MP did, “We say that education is essential for the progress of the nation, and education is 
free. Two things are necessary for the progress of the nation – education and health. Both 
should be free. Both should be the right of every member of the community, and Opposition 
members will never be satisfied until a health scheme is introduced here that entitles 
everybody from the day of their birth to the day of their death to the fullest measure of 
treatment in respect of their health, so as to build and maintain a healthy and strong 
nation.”86 Despite such opposition, the new scheme passed and was introduced in 1960. 
 
Notwithstanding the introduction of the co-payments, prescription volumes increased from 
24.6 million in 1959 to 60, to 60.4 million in 1968 to 69, and Commonwealth expenditure 
rose from $43 million to $100 million at the end of the decade.87 
Issues of affordability and sustainability still plague the Pharmaceutical Benefits Scheme. To 
limit the cost to the public of listing particular medicines, medicines are listed on the PBS 
only if they satisfy two main criteria – community need and cost effectiveness. 88 A medicine 
meets the ‘community need’ criterion if it is necessary to maintain the health of the 
community.’ 89 A medicine is considered to be ‘cost effective’ if its cost can be justified by 
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the improved health outcomes it brings.90 The later criterion is non-negotiable - the National 
Health Act 1953 (Cth) requires the Pharmaceutical Benefits Advisory Committee to assess 
cost-effectiveness.91 If the Pharmaceutical Benefits Advisory Committee is satisfied that a 
medicine meets both criteria, then the Department of Health negotiates its price with the 
supplier.92  
 
Other strategies employed to ensure the PBS is affordable, and continues to ensure 
accessibility to medicines, include specifying a maximum number of repeat prescriptions an 
individual can have subsidised, and restricting subsidised medicines to specific therapeutic 
uses only.93  
 
This year, the Department of Health unveiled the Pharmaceutical Benefits Scheme Access 
and Sustainability Package 2015 – an amalgamation of 20 measures which together are 
intended to ensure that high cost medicines will be accessible to more people over the next 
5 years.94 In particular, the Sixth Community Pharmacy Agreement 2015, which is a part of 
the Package, will provide $18.9 billion over five years to 5400 community pharmacies to 
support subsidisation of high cost medicines.95  
 
Alternate Access Schemes: Section 100 Programs 
 
In addition to the medicines subsidised through the Pharmaceutical Benefits Scheme, there 
are a number of other drugs that are subsidised, but are distributed under alternative 
arrangements.96 These alternative arrangements are provided for under Section 100 of the 
National Health Act 1953 (Cth): 
 
“(1) The Minister may make special arrangements for, or in relation to, providing 
that an adequate supply of pharmaceutical benefits will be available to persons: 
(a) who are living in isolated areas; or 
(b) who are receiving treatment in circumstances in which pharmaceutical benefits 
are inadequate for that treatment”97  
 
There are a number of Section 100 programs, all of which are designed to ensure that 
patients are able to access the medicines they require.  
 
The largest Section 100 program is the Highly Specialised Drugs Program (HSDP).98 The HSDP 
subsides high cost drugs that treat complex conditions that require hospital supervision. 
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Conditions covered on the scheme include cancers, and hepatitis.99 The average annual 
growth in the HSDP has been around 6.38% from 2009 to 2014.100 
 
The Efficient Funding of Chemotherapy Program, an initiative of the Section 100 Program 
that provides chemotherapy at an accessible price, has had an average annual growth rate 
of 62% since its inception in 2009.101 
 
The Life Saving Drugs Programme102 is a separate scheme that provides eligible patients with 
subsidised access to ten expensive drugs. 103  The ten drugs currently listed all treat serious 
medical conditions that are: rare, identifiable with reasonable diagnostic precision, and 
sufficiently debilitating.104 Among other criteria, the drug must be economically burdensome 
for patients.105 Currently, 268 patients are being treated on the Life Saving Drugs 
Programme.106 On average, each patient costs the Australian Government over $300000 a 
year107 even though none of the LSDP drugs cure diseases.108. 
 
The Orphan Drugs Program is a scheme designed to encourage drug manufacturers to 
develop and market ‘orphan drugs.’109 An ‘orphan drug’ is defined in Regulation 16 H (2) of 
the Therapeutic Goods Regulation 1990 (Cth) as a drug that: 
 
“(a) [is] intended to treat, prevent or diagnose a rare disease; or 
 (b) [is] not commercially viable to supply to treat, prevent or diagnose another 
disease or condition.”110 
 
Regulation 45(12) of the Therapeutic Goods Regulation 1990 (Cth) provides that companies 
do not have to pay to have ‘orphan drugs’ considered by the Pharmaceutical Benefits 
Advisory Committee for listing on the Pharmaceutical Benefits Scheme.111  
 
Since the introduction of the Orphan Drug Program, the annual number of orphan drug 
designations has increased from an average of 13 in the first few years of the program to 20 
approvals in 2009.112 42% of all the drugs covered by the Orphan Drug Program have been 
for cancer.113  
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While increasing the range of drugs is beneficial for recovery, particularly to those suffering 
from rare diseases, the Orphan Drugs Program does not ensure that they are economically 
accessible. Thus, patients might still have to forego treatment due to price.  
 
Other avenues to access medicines 
 
Evidently, not all high cost medicines are subsidised through the PBS, and even those that 
are may not be subsidised for all the types of cancers for which it may prove beneficial. 
Patients that need access to a high-cost medicine that is not subsidised by the PBS do have 
alternative, although ad hoc, avenues for access. At the discretion of a pharmaceutical 
company, access to a drug may be granted to a patient for free, at a significant discount, or 
free of charge after an initial commitment to buy the first courses of treatment. Another 
option is for patients to seek treatment through the public hospital system. Public hospitals 
are funded by a separate budget, and are autonomous with regards to decisions about what 
drugs they buy, to whom they dispense drugs, and for what reasons. This is typically 
managed through the Drug and Therapeutics Committee that has governance over the 
hospital formulary. Access to free medicines may also be granted via clinical trials (if one 
exists), but being accepted into these trials is not straightforward and access may be limited 
by eligibility criteria, size of the trial, and location of the trial. In rare instances, the 
government may also be pressured to create special funding streams, outside of the PBS, for 
specific expensive medicines such as the Herceptin Program to fund transtuzumab for breast 
cancer patients.114 
 
All of these approaches can lead to inconsistent decisions, as neither pharmaceutical 
companies nor hospitals are obliged to provide access to medicines, and are not governed 
by a central decision making body. Access to clinical trials can be limited for the reasons 
already stated, while the creation of special funding streams for particular diseases by 
governments can also be criticised for discriminating against patients suffering from other 
life-threatening diseases for which expensive medicines may help, yet remain unfunded.  In 
all cases the unpredictability and financial pressures that result when patients must raise the 
money for treatment themselves, and are faced with the prospect of forgoing treatment 
only because they cannot afford it, are highlighted in the Senate Inquiry as major stressors 
for already vulnerable patients. 
 
DISCUSSION 
 
Value of the right to health 
 
This analysis has demonstrated that there is no broad common law or legislative right to 
health in Australia because the right to the highest attainable standard of health, as outlined 
in Article 12 of the International Covenant on Economic, Social and Cultural Rights 1976, has 
not been ratified into domestic law. This has been the case for over 50 years, and is unlikely 
to change. Unfortunately for patients, this means that the Australian Government is under 
no legal duty to ensure that they are able to access medicines-including those that might 
extend their lives. Further, no domestic legal action can be brought against a pharmaceutical 
company for not providing the medicines they produce at affordable prices. Thus, the 
international right to health ensures no legal benefit in Australian courts. This is true even 
for disadvantaged parties such as those with rare diseases for whom there are limited 
therapeutic options, or diseases that can only be treated using very expensive medicines.  
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While this situation may appear unjust, there are very strong arguments for the right to 
health to remain absent from Australian law. The primary argument against ratifying rights 
in Australia is; if the right to health were justiciable via legislation, courts would have the 
power to make resource allocation decisions if the right to health is activated in a case. 
Because the public does not elect judges, there are legitimate concerns that judges should 
not be given the power to make decisions that affect all citizens. At least in theory, 
government bodies, such as the various Departments of Health and their nominated 
committees such as PBAC, are better suited to be making resource allocation decisions 
because they are answerable to citizens by way of elections. 
 
Further, some claim that Australia already does enough to protect the right to health, 
namely via Medicare and the PBS; an explicit right to health is therefore unnecessary.115 
Others propose that characterising health, as a ‘right,’ would place an undue financial 
burden on the government to provide everyone with adequate healthcare, which is 
impossible in a resource-limited society.  
 
This does not mean that the notion of a right to health is irrelevant in Australia - it does 
serve a rhetorical purpose. Dworkin claimed that categorising something as a right makes 
that ‘good’ more important than other ‘goods.’ In Australia, health has undeniably become 
more important since the right to health was incorporated into international law in 1966. In 
1981-82, 6.3% of GDP (10.8 billion dollars) was spent on health care, whereas, in 2013-2014, 
9.8% of GDP  (154.6 billion dollars) was spent on health measures.116 Evidently, health care 
has become increasingly important to the Australian Government, as it has for international 
law making bodies. While Australian Governments have not necessarily been motivated to 
increase their expenditure on health because of international law, it seems likely that they 
would have been influenced by the plethora of international commentary on the right to 
health, and changing public perceptions about the importance of health. 
 
The significance of rights as a rhetorical device is also evident in our finding that human 
rights language is employed in the purpose statements of many, if not all, domestic access 
policies. As we have shown, Medicare, the PBS and other health access schemes are 
explicitly underpinned by principles such as equity, social justice and universality, which 
focus on the rights of (disadvantaged) individuals rather than only the good of the 
collective.117  
 
We have also shown that there are programs in place, such as the Highly Specialised Drugs 
Program and the Life Saving Drugs Program, which provide concrete examples of Australia’s 
commitment to the rights of at least some individuals, irrespective of cost. These programs 
exist because the patients with the highest medical need are often the patients with the 
least capacity to fund their own treatment.118 Proponents of the right to health argue that 
these patients should not be denied treatment simply because the medicines they need are 
incredibly expensive. The existence, and rapid growth, of these programs shows that society 
is generally unable to tolerate denying life-saving or life-sustaining treatment to patients, 
particularly where those patients are recognisable and where there is a clear person 
responsible for making the allocation decision. Philosopher Albert Jonson described this 
phenomenon as ‘the rule of rescue’ – an innate human impulse to save identifiable 
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individuals at risk of imminent death no matter how great the cost or small the likelihood of 
benefit.119 
 
Implications for health resource allocation in Australia 
 
While it is understandable that people in need of healthcare would use whatever rhetorical 
devices they can, and while the rule of rescue describes an admirable human reaction, these 
arguments can also confound resource allocation decisions. Clearly, in a resource limited 
health system, ignoring the cost of treatments altogether is impractical, and some regard 
must be had to the cost-effectiveness and affordability of treatments before they are 
subsidised. For this reason, those making resource allocation decisions inevitably have to 
balance their commitment to addressing the needs of individuals against the need to ensure 
the greatest good for the greatest number of people. Australia’s health system is, therefore, 
characterised by an ongoing tension between a commitment to utility and a commitment to 
individual rights. 
 
In spite of the impracticalities of making resource allocation decisions based solely on the 
right to health, there does appear to be an international and domestic shift towards 
providing more patients with higher cost drugs. Nonetheless, ways of minimising the cost of 
providing high-cost medicines to the population at subsidised rates are necessary for this 
shift to be sustainable. Some commentators have recommended integrating the Section 100 
Programs into the Pharmaceutical Benefits Scheme to minimise unnecessary administration 
fees. Others have recommended negotiating new arrangements with Australian 
pharmaceutical companies. Ultimately, a solution needs to be found if right to health 
premised programs are to remain cost-effective and affordable. 
 
CONCLUSION 
 
As Justice Kirby stated in his Inaugural Lecture to the Australian Institute of Health Law and 
Ethics, ‘it is possible for us to recognise, in recent years, a growing understanding that the 
allocation of healthcare resources has an ethical dimension.’120 However, as this analysis 
makes clear, there is no universal model for resolving the ethical problems of resource 
allocation. While the right to health model serves an important rhetorical function, and 
encourages governments to ensure that medicines—including high cost medicines—are 
accessible to all patients who need or want them, this is clearly unfeasible in a resource-
limited system. 
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